The seventh Longevity Investors Conference brings science, capital and candid debate together in the Swiss Alps this September.
The Longevity Investors Conference (LIC) returns to Le Grand Bellevue in Gstaad, Switzerland, from 14 to 17 September, bringing together investors, founders, scientists and clinicians for four days of discussion centred on one of the sector’s defining questions – not simply what will extend healthy lifespan, but what will attract the capital needed to make it happen. Now in its seventh edition, the meeting has established itself – application-only, deliberately small – as a fixture on the longevity calendar, with this year’s programme placing equal emphasis on scientific scrutiny, investment strategy and translational medicine.
Against a backdrop of growing institutional interest in healthy longevity, the conference arrives at a time when the sector is shifting from early promise towards clinical execution. The agenda reflects that evolution, pairing established names from geroscience with entrepreneurs, investors and industry leaders whose decisions may ultimately determine which therapies progress beyond the laboratory.
Longevity.Technology: While there is no shortage of longevity conferences these day, relatively few focus on what ultimately determines whether that future ever reaches patients. Science may generate the hypotheses, but capital carries them through toxicology, manufacturing, clinical trials and, if all goes well, into healthcare systems. That is where the Longevity Investors Conference has carved out its niche over the past seven years. Established enough to attract serious investors, founders and researchers – yet deliberately intimate enough to encourage conversations that continue long after the panels end – LIC has become less a showcase than a piece of the field’s infrastructure. As longevity biotechnology matures, that distinction matters. Good science still matters, of course; good science funded by informed, patient capital matters rather more. After all, discoveries rarely walk themselves into the clinic carrying their own Series B.
Science meets scrutiny
This year’s programme is built around a series of debates and masterclasses that tackle questions currently shaping the longevity field. Among the headline sessions is How to Tell the Difference, Spotting Real Aging Science, featuring epigenetic clock pioneer Dr Steve Horvath alongside Dr Collin Ewald of Novartis and Professor Evelyne Yehudit Bischof, examining how investors can distinguish robust geroscience from persuasive marketing.
Elsewhere, Same Patient, Three Bills brings together Dr Nir Barzilai, Dr Jordan Shlain, Dr Adeel Khan and Dr David Barzilai to explore competing models of longevity medicine and the practical question of which approaches are likely to prove scalable, defensible and commercially sustainable. Meanwhile, Professor Michael Levin joins philosopher Jonathan Anomaly and R3 Bio cofounder and COO Alice Gilman for a discussion examining regenerative biology, embryo selection and other ideas that have begun the journey from speculative science towards commercial reality.
Dave Asprey will also make his first appearance in Switzerland to discuss the intersection of longevity, artificial intelligence and human performance, while esteemed geroscientist Dr Aubrey de Grey joins LEV Foundation’s Director of Supercentenarian Research Natalie Coles and LIC co-founder Dr Tobias Reichmuth for a session exploring whether exceptional longevity can offer clues to the next generation of therapeutic opportunities.
Also on the roster is Max Marchione, who built Superpower into a billion-dollar health company before turning twenty-six; his presence signals a widening of the room, one that now stretches from geroscience’s elder statesmen to founders barely out of their twenties.
Beyond the auditorium
As in previous years, LIC’s organisers place considerable emphasis on conversations away from the main stage. Roundtable discussions, networking events and informal gatherings are designed to foster direct dialogue between founders and investors, while a new addition for 2026 – the Moonshot Dinner – promises an intimate forum for exploring some of the field’s more ambitious life-extension technologies with the founders developing them.
The programme also reflects the conference’s distinctive alpine setting. Guided mountain walks, morning runs, breathwork sessions and cold-water immersion sit alongside receptions, dinners and social events; longevity, in other words, is intended to be experienced as well as debated.
Following the capital
The conference’s partner ecosystem offers another indication of how the sector is evolving. This year’s addition of HSBC Private Bank as a strategic partner sits alongside returning organisations including Maximon, Tomorrow Biostasis and Maerki Baumann, while Niagen Bioscience joins as the first publicly traded longevity company listed on NASDAQ to partner with the event.
Reflecting on the conference’s role, co-founder Marc P Bernegger said: “The capital entering longevity has changed. It is more serious, more informed, and more willing to back the science early. LIC is where that capital and that science actually meet.”
LIC also continues its Start-Up Innovation Catalyst, giving a carefully selected group of early-stage companies the opportunity to present directly to investors. Previous participants have included Cellcolabs, Gero AI, Deciduous Therapeutics, Mito RX Therapeutics and GlycanAge – companies that have gone on to become familiar names within the longevity ecosystem.
Dr Tobias Reichmuth believes that enduring appeal stems from proximity rather than scale. “We built LIC so investors can get close enough to the science, and the scientists, to judge the boldest bets for themselves. That is what brings people back to Gstaad year after year.”
Beyond the check
Compelling biology will only carry longevity so far; mainstream medicine is bought, eventually, with capital patient enough to sit through toxicology, manufacturing and the long attrition of clinical trials. It is not the most glamorous chapter – but it is usually the one that decides how the story ends.
The 2026 Longevity Investors Conference takes place from 14–17 September at Le Grand Bellevue in Gstaad, Switzerland. For more information or to apply, please CLICK HERE.
